ISIS Pharmaceuticals, Inc.
Carlsbad, CA 92010
Share:
Isis Pharmaceuticals Receives Key Patent for Pathogen Identification Methodology Used in Ibis Biosensor System
Isis Pharmaceuticals Receives Key Patent for Pathogen Identification Methodology Used in Ibis Biosensor System New Patent Is Fundamental to Biosensor Technology Developed by Ibis Division of Isis CARLSBAD, Calif., Sept. 20 -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that the United States Patent and Trademark Office (USPTO) has issued to Isis U.S. Patent No. 7,108,974 (the '974...
Read More »Isis Pharmaceuticals to Present at the 22nd Annual Piper Jaffray Health Care Conference
CARLSBAD, Calif., Nov. 23, 2010 -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Piper Jaffray's 22nd Annual Health Care Conference on Tuesday, November 30, 2010 at 10:00 a.m. ET at The New York Palace Hotel. A live audio webcast of the presentation will be available on the Investors & Media...
Read More »Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
Isis will own 18 percent of Altair and will receive milestones and royalties on antisense drugs developed by Altair Altair to conduct clinical development of ISIS 369645 for asthma CARLSBAD, Calif. and SAN FRANCISCO, Oct. 16 / -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and Thomas, McNerney & Partners, LLC, announced today that Altair Therapeutics Inc., a new venture capital-funded biotechnology...
Read More »Isis Acquires Symphony GenIsis
ISIS 301012 now under Isis' ownership in preparation for partnering CARLSBAD, Calif., Sept. 27 -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), today announced its purchase of all of the equity of Symphony GenIsis at the pre-negotiated price of $120 million. Prompting this transaction, on September 13, 2007, Isis announced its metabolic disease-focused collaboration with Ortho-McNeil, Inc., a Johnson...
Read More »Isis Pharmaceuticals Receives Key Patent for Pathogen Identification Methodology Used in Ibis Biosensor System
Isis Pharmaceuticals Receives Key Patent for Pathogen Identification Methodology Used in Ibis Biosensor System New Patent Is Fundamental to Biosensor Technology Developed by Ibis Division of Isis CARLSBAD, Calif., Sept. 20 -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that the United States Patent and Trademark Office (USPTO) has issued to Isis U.S. Patent No. 7,108,974 (the '974...
Read More »